Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer Ammu V. V. V. Ravi KiranGarikapati Kusuma KumariPraveen T. Krishnamurthy PRECLINICAL STUDIES 02 August 2021 Pages: 1 - 9
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents Xia XueYingjie ZhangXiaogang Zhao PRECLINICAL STUDIES 31 August 2021 Pages: 10 - 20
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase Tapasvi ModiDavid Gervais PRECLINICAL STUDIES Open access 01 September 2021 Pages: 21 - 29
Antineoplastic activity of products derived from cellulose-containing materials: levoglucosenone and structurally-related derivatives as new alternatives for breast cancer treatment Damian Ignacio DelbartGerman Francisco GiriAlejandro Jorge Urtreger PRECLINICAL STUDIES 03 September 2021 Pages: 30 - 41
Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment Damian Ignacio DelbartGerman Francisco GiriAlejandro Jorge Urtreger Author Correction 29 November 2021 Pages: 42 - 42
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non‐small cell lung cancer Xue ZhouNing WangQi Wu PRECLINICAL STUDIES 09 September 2021 Pages: 43 - 57
A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target Ji-li XuYong Guo PRECLINICAL STUDIES 13 September 2021 Pages: 58 - 67
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK) Georgina Meneses-LorenteStephen FowlerNassim Djebli PHASE I STUDIES Open access 21 August 2021 Pages: 68 - 80
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma Hani BabikerPeter J. SchlegelAllyson J. Ocean PHASE I STUDIES 21 August 2021 Pages: 81 - 90
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors Yannis MetaxasCarmen KahattAnastasios Stathis PHASE I STUDIES 28 August 2021 Pages: 91 - 98
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors Shumei KatoJacob J. AdashekDavid S. Hong PHASE I STUDIES 01 September 2021 Pages: 99 - 105
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer Shota OmoriHideyuki HaradaToshiaki Takahashi PHASE I STUDIES 08 September 2021 Pages: 106 - 114
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies Joleen M. HubbardJun YinBrian A. Costello PHASE I STUDIES 13 September 2021 Pages: 115 - 123
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study Rony DevLinda L. ZhongAung Naing PHASE I STUDIES 24 September 2021 Pages: 124 - 133
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma Daniel H. AhnPedro Luiz Serrano Uson JuniorMitesh J. Borad PHASE I STUDIES 31 August 2021 Pages: 134 - 141
Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs Takehiro HiraiAsuka SuzukiMasaaki Matsuura PHASE III STUDIES 21 August 2021 Pages: 142 - 150
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer Lan WangHaiyan LouYun-Mei Yang Short Report Open access 21 July 2021 Pages: 151 - 156
Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors Limin ZhuBrian HobbsDavid S. Hong Short Report 02 August 2021 Pages: 157 - 162
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition Julian TaugnerLukas KäsmannFarkhad Manapov Short Report Open access 05 August 2021 Pages: 163 - 171
In vitro selection of DNA aptamers against human osteosarcoma Khaliunsarnai TsogtbaatarDiana A. SousaLigia Rodrigues Short Report 12 August 2021 Pages: 172 - 181
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease Satoshi IgawaMasanori YokobaKatsuhiko Naoki SHORT REPORT 20 August 2021 Pages: 182 - 189
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report Francesco GelsominoAlessandro Di FedericoStefania Salvagni Short Report Open access 26 August 2021 Pages: 190 - 193
Successful treatment of a case of hormone receptor–positive metastatic extramammary Paget disease with tamoxifen Kohsuke IsomotoKoji HarataniKazuhiko Nakagawa Short Report 31 August 2021 Pages: 194 - 197
Modulation of peritumoral fibroblasts with a membrane-tethered tissue inhibitor of metalloproteinase (TIMP) for the elimination of cancer cells Yihe ZhangShiyu LiuMeng Huee Lee Short Report 14 September 2021 Pages: 198 - 208
Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication Yizhuo ZhaoWei PengHuiying Yan Short reports 16 August 2021 Pages: 209 - 214